A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate-resistant prostate cancer (mCRPC) patients von Bryce, Alan Haruo, Dronca, Roxana Stefania, Costello, Brian Addis, Aparicio, Ana, Subudhi, Sumit Kumar, O'Donnell, Joseph F., Jimeno, Jose, Yim, Christina Yeaeun, Ames, Tyler David, Price, Matthew, Karp, Daniel D.

Volltext